Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 40

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 GQ Bio Therapeutics GmbH (net of cash acquired)(16,702)— Purchases of fixed assets(8,548)(2,836)Purchases of available-for-sale investments(69,629)(56,055)Sales of available-for-sale investments69,250 43,361 Net cash used in investing activities(25,629)(15,530)Financing activities:  Payment of employee withholding taxes on restricted stock unit vests(181)(4)Repayment of Term loan A facility(2,813)(2,813)Net cash used in financing activities(2,994)(2,817)Net increase in cash and cash equivalents6,836 30,754 Cash and cash equivalents, beginning of period276,774 153,298 Cash and cash equivalents, end of period$283,610 $184,052 Supplemental cash flow information: Cash paid for interest$2,715 $3,969 Net cash paid (received) for income taxes$286 $(245)Non-cash investing and financing activities:  Fixed assets included in accounts payable and accrued liabilities$767 $607 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q1 2025 Form 10-Q  |  Page 8

PACIRA BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—DESCRIPTION OF BUSINESS

Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) delivers innovative, non-opioid pain therapies to transform the lives of patients. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome, or pMVL, drug delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time. EXPAREL is currently indicated to produce postsurgical local analgesia via infiltration in patients aged six years and older, and postsurgical regional analgesia via an interscalene brachial plexus block in adults, a sciatic